Allergy Therapeutics Balance Sheet Health
Financial Health criteria checks 1/6
Allergy Therapeutics has a total shareholder equity of £3.7M and total debt of £23.1M, which brings its debt-to-equity ratio to 622.8%. Its total assets and total liabilities are £64.8M and £61.1M respectively.
Key information
622.8%
Debt to equity ratio
UK£23.10m
Debt
| Interest coverage ratio | n/a |
| Cash | UK£12.92m |
| Equity | UK£3.71m |
| Total liabilities | UK£61.12m |
| Total assets | UK£64.83m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: AGYT.F's short term assets (£33.5M) exceed its short term liabilities (£20.5M).
Long Term Liabilities: AGYT.F's short term assets (£33.5M) do not cover its long term liabilities (£40.6M).
Debt to Equity History and Analysis
Debt Level: AGYT.F's net debt to equity ratio (274.6%) is considered high.
Reducing Debt: AGYT.F's debt to equity ratio has increased from 6.5% to 622.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AGYT.F has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: AGYT.F has less than a year of cash runway if free cash flow continues to reduce at historical rates of 50.6% each year